Zevra Therapeutics, Inc. ZVRA Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $106.47M+351% | $23.61M-14.0% | $27.46M+170% | $10.16M-64.5% | ||
| $16.48M+122% | $7.42M+152% | $2.95M+1,227% | $222K-89.2% | ||
| $89.99M+456% | $16.2M-33.9% | $24.52M+147% | $9.94M-62.6% | ||
| 84.5%+15.9pp | 68.6%-20.7pp | 89.3%-8.5pp | 97.8%+5.0pp | ||
| $12.74M-69.7% | $42.1M+5.8% | $39.81M+101% | $19.8M+94.9% | ||
| $77.62M+41.5% | $54.87M+59.9% | $34.31M+128% | $15.04M— | ||
| $3.86M-38.1% | $6.24M+520% | $1.01M+6.6% | $944K+267% | ||
| $90.36M-6.8% | $96.96M+30.8% | $74.12M+40.6% | $52.73M+152% | ||
| —— | -$87M-75.4% | -$49.6M-16.5% | -$42.57M— | ||
| $7.98M+8.5% | $7.35M+390% | $1.5M+348% | $335K+48.2% | ||
| $149.62M+4,870% | -$3.14M— | —— | $15.76M+196% | ||
| —— | —— | —— | $0+100% | ||
| $148.33M— | $0— | —— | —— | ||
| $86.68M+196% | -$90.14M-95.7% | -$46.05M— | —— | ||
| $3.45M-77.6% | $15.37M— | $0— | —— | ||
| $83.23M+179% | -$105.51M-129% | -$46.05M— | —— | ||
| 78.2%+525pp | -446.9%-279pp | -167.7%— | —— | ||
| $1.33+158% | -$2.28— | —— | —— | ||
| $1.37+161% | -$2.26-73.8% | -$1.30— | —— | ||
| 223.6M— | —— | —— | —— | ||
| 220.1M+23.9% | 177.7M+28.3% | 138.5M+0.4% | 137.9M+21.7% | ||
| $3.86M-38.1% | $6.24M— | —— | —— | ||
| -$2.18M— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $6.95M+209% | $2.25M-50.5% | $4.54M— | —— | ||
| $12.74M-69.7% | $42.1M+5.8% | $39.81M+101% | $19.8M+94.9% | ||
| —— | —— | —— | —— | ||
| -$57.64M+33.7% | -$87M-75.4% | -$49.6M-16.5% | -$42.57M-638% | ||
| -$53.59M+33.5% | -$80.61M-65.9% | -$48.6M-16.8% | -$41.62M-610% | ||
| -$53.59M+33.5% | -$80.61M-65.9% | -$48.6M-16.8% | -$41.62M-610% | ||
| -50.3%+291pp | -341.4%-164pp | -177%+233pp | -409.6%-438pp | ||
| -$57.64M+33.7% | -$87M-75.4% | -$49.6M-16.5% | -$42.57M-638% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Zevra Therapeutics, Inc.'s revenue?
- Zevra Therapeutics, Inc. (ZVRA) generated $122.3M in revenue over the trailing twelve months, up 201.3% year over year.
- Is Zevra Therapeutics, Inc. profitable?
- Zevra Therapeutics, Inc. reported $124.2M in net income over the trailing twelve months, a 101.6% net margin.
- What are Zevra Therapeutics, Inc.'s profit margins?
- Gross margin is 86.1% and operating margin is -103.9%, with a 101.6% net margin.
- What is Zevra Therapeutics, Inc.'s earnings per share?
- Zevra Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $1.99.
- Where does Zevra Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
